Immune Checkpoints as Therapeutic Targets in Autoimmunity

Antibodies that block the immune checkpoint receptors PD1 and CTLA4 have revolutionized the treatment of melanoma and several other cancers, but in the process, a new class of drug side effect has emerged—immune related adverse events. The observation that therapeutic blockade of these inhibitory re...

Descripción completa

Detalles Bibliográficos
Autores principales: Paluch, Christopher, Santos, Ana Mafalda, Anzilotti, Consuelo, Cornall, Richard J., Davis, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186808/
https://www.ncbi.nlm.nih.gov/pubmed/30349540
http://dx.doi.org/10.3389/fimmu.2018.02306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186808/
https://www.ncbi.nlm.nih.gov/pubmed/30349540
http://dx.doi.org/10.3389/fimmu.2018.02306

Ejemplares similares